Inhibikase Therapeutics Inc Stock Price, News & Analysis

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced interim three-month results from chronic toxicology studies for its oral drug IkT-148009, aimed at treating Parkinson's disease. The studies, involving rats and non-human primates, revealed an improved toxicology profile with increased NOAEL measurements, suggesting enhanced safety with prolonged dosing. Following FDA review of these results, Inhibikase plans to initiate a Phase 2a study in 2022, evaluating IkT-148009's effects on up to 120 Parkinson's patients. The selective c-Abl kinase inhibitor demonstrates promising potential for better safety and tolerability.

Inhibikase Therapeutics (Nasdaq: IKT) announced a $385,388 research grant from the U.S. National Institute of Neurological Disease and Stroke to evaluate IkT-148009 in a preclinical model for Multiple System Atrophy (MSA). This grant supports research to understand MSA mechanisms and explore the therapeutic potential of IkT-148009, a selective c-Abl kinase inhibitor, which has shown promise in treating Parkinson's disease. Currently, no approved therapies exist for MSA, impacting approximately 20,000 individuals in the U.S.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced that CEO Dr. Milton Werner will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation is scheduled for September 13 at 7:00 AM ET. A webcast will be available on Inhibikase's website for on-demand viewing, with an archived replay accessible for 30 days post-event. Inhibikase focuses on developing therapeutics for Parkinson's disease and related conditions, including their lead program IkT-148009, which has completed Phase 1 studies and is underway in Phase 1b trials.

Inhibikase Therapeutics (Nasdaq: IKT) reported a net loss of $2.6 million for Q2 2021, compared to $0.4 million in Q2 2020. R&D expenses surged to $2.4 million, driven by clinical trial costs. The company initiated a Phase 1b study for IkT-148009, aimed at treating Parkinson's disease, and plans to submit 13-week toxicology studies to the FDA. They also expect to file an IND for IkT-001Pro for Chronic Myeloid Leukemia in Q3 2021. Cash reserves stand at $46.8 million, expected to fund operations until mid-2023.

Inhibikase Therapeutics (Nasdaq: IKT) announced FDA clearance for a Phase 1b extension study of IkT-148009, a drug targeting Parkinson's disease, after positive safety and tolerability results from a Phase 1 trial in healthy volunteers. This next phase will evaluate the drug's effects on Parkinson's patients, following promising outcomes in preclinical studies. With no significant adverse events reported among 42 subjects in the initial trial, the company aims to advance its therapeutic pipeline, addressing a disease affecting over 1 million individuals in the U.S.

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) announced the closure of its public offering of 15 million shares at $3.00 each, raising gross proceeds of $45 million. This funding aims to support a Phase 1b extension study for IkT-148009 targeting Parkinson's disease, production for upcoming clinical trials, and general R&D activities. The underwriters also have a 45-day option to purchase an additional 2.25 million shares. The offering was registered with the SEC and the final prospectus is available online.

Inhibikase Therapeutics (Nasdaq: IKT) announced a public offering of 15 million shares at $3.00 each, totaling approximately $45 million in gross proceeds. The offering will close on June 18, 2021, subject to customary conditions. Proceeds will fund a Phase 1b extension study for IkT-148009 in Parkinson's patients, production for subsequent studies, and general R&D efforts. The underwriters have a 45-day option to purchase an additional 2.25 million shares. The offering is registered with the SEC under Form S-1.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced that CEO Dr. Milton Werner will present at two upcoming virtual healthcare conferences. The first is the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:30 PM ET, followed by the LD Micro Virtual Invitational XI on June 10, 2021, at 11:30 AM ET. Dr. Werner will discuss the clinical pharmacokinetics and adverse event profile of IkT-148009, the company's leading treatment for Parkinson's disease. Webcasts will be available for on-demand viewing on the company's website for 30 days after each event.

Inhibikase Therapeutics (Nasdaq: IKT) reported Q1 2021 financial results, highlighting key developments in its Parkinson's disease treatment programs. The company accelerated the Phase 1 study of IkT-148009, aiming for regulatory approval to begin patient dosing by Q3 2021. Toxicology studies for IkT-148009 are ongoing, with an IND application for IkT-001Pro planned for submission in Q3 2021. Financially, Inhibikase reported a net loss of $2.6 million, up from $0.5 million in Q1 2020, with R&D expenses rising to $2.4 million due to clinical trial costs. Cash reserves stood at $9.6 million.